+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
KRAS Inhibitor Market - Global Forecast 2025-2030- Product Image
KRAS Inhibitor Market - Global Forecast 2025-2030- Product Image
Sale

KRAS Inhibitor Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6125434
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The KRAS inhibitors market is entering a transformative phase, driven by rapid advancements in precision oncology, regulatory momentum, and emerging personalized treatment pathways. Senior executives will find this environment marked by scientific breakthroughs, evolving supply chain strategies, and shifting competitive dynamics across regions.

Market Snapshot: Current Outlook and Growth Dynamics

The global KRAS inhibitor market demonstrates robust growth, propelled by recent therapeutic innovations and expanded regulatory approvals. Notable drivers include the integration of next-generation covalent, allosteric, and non-covalent molecules targeting diverse mutant KRAS isoforms. Heightened investment in biotechnology, an increase in early-phase clinical pipeline activity, and supportive policies across the Americas and Asia-Pacific contribute to market expansion. The implementation of adaptive regulatory pathways has accelerated timelines from investigational new drug submission through to market entry, compressing development cycles and incentivizing innovation. Moreover, partnership-driven approaches—especially between diagnostics and pharmaceutical firms—enable optimized patient stratification and broadened access to advanced therapies.

Scope & Segmentation of the KRAS Inhibitors Market

  • Indication: Colorectal cancer, non-small cell lung cancer, and pancreatic cancer each drive unique application and development strategies for KRAS inhibitor therapies.
  • Mechanism of Action: Technologies covered include allosteric inhibitors, covalent inhibitors, and non-covalent inhibitors, addressing a broad mutational spectrum with varied safety and effectiveness profiles.
  • Mutation Type: Focus on G12C, G12D, and G12V mutations, with differential clinical advancement and pipeline activity across each mutation subtype.
  • Dosage Form: Injectable solutions enable rapid dose modulation, while oral tablet forms enhance patient convenience and support ambulatory care uptake.
  • End User: Cancer care centers, hospitals, retail pharmacies, and specialty clinics each represent high-adoption channels, scaling access to therapy.
  • Distribution Channel: Hospital pharmacy, online pharmacy, retail pharmacy, and specialty pharmacy are examined for their respective roles in supply, patient reach, and adherence programs.
  • Regions: Americas (with detailed breakdowns for the United States including California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; as well as Canada, Mexico, Brazil, Argentina), EMEA (covering key European countries, Gulf Cooperation Council states, and leading African markets), and Asia-Pacific (including major healthcare hubs such as China, India, Japan, South Korea, Australia, and Southeast Asian economies).
  • Key Companies: Profiles of Amgen Inc., Mirati Therapeutics, Inc., Revolution Medicines, Inc., Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Inc., Carmot Therapeutics, Inc., and Hua Medicine Co., Ltd.

Key Takeaways for Strategic Decision-Making

  • Pipeline diversification is accelerating as organizations target a wider range of KRAS mutations beyond G12C, with early-phase assets advancing rapidly based on preliminary in vivo efficacy data.
  • Combination regimens with checkpoint and kinase inhibitors are reshaping clinical trial designs, with initial data indicating improved outcomes in refractory cancers where monotherapies have shown limitations.
  • Precision in patient selection is dramatically increasing due to improvements in real-time diagnostic tools such as liquid biopsies and next-generation sequencing platforms.
  • Strategic collaborations are driving the integration of companion diagnostics into early clinical development, easing regulatory approvals and supporting value-based reimbursement negotiations.
  • Vertical integration within supply chains is becoming a prevalent response to ongoing tariff and geopolitical pressures, strengthening manufacturing resilience and stability through dual-sourcing and co-investment with contract partners.
  • Cross-sector partnerships between drug companies and academic or diagnostic groups are accelerating adaptive trial approaches and broadening early patient access in regions with high unmet oncology needs.

Tariff Impact and Supply Chain Adaptations

The 2025 introduction of renewed U.S. import tariffs has added complexity throughout the pharmaceutical supply chain, particularly for KRAS inhibitor components sourced internationally. Companies are responding by localizing synthesis and formulation steps, forming domestic partnerships, and qualifying multiple suppliers to mitigate cost volatility and ensure continuity for commercial and trial-stage products. These tariff-driven adjustments are fostering new models of collaboration with contract development and manufacturing organizations, reinforcing industry resilience and buffering against future disruptions.

Methodology & Data Sources

This report applies a mixed-method research framework, incorporating qualitative expert interviews with oncology advisors, pharmacologists, and supply chain strategists. Systematic reviews of peer-reviewed journals, clinical registries, patent filings, and regulatory updates validate findings. Scenario mapping and qualitative coding ensure comprehensive analysis and reliability.

Why This Report Matters: Actionable Insights for Leaders

  • Gain a panoramic view of current and future trends shaping KRAS inhibitor innovation, clinical integration, and competitive positioning.
  • Identify the operational impacts of regulatory shifts, supply chain vulnerabilities, and evolving reimbursement frameworks across established and emerging regions.
  • Leverage strategic guidance to optimize portfolio diversification, enhance diagnostic collaboration, and reinforce supply chain adaptability in fluctuating market conditions.

Conclusion

As the KRAS inhibitor market evolves, organizations capable of integrating clinical, regulatory, and supply strategies will shape the next phase of growth in precision oncology. Leaders prepared to act on these insights can secure long-term value and establish sustained competitive advantage.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of next-generation covalent KRAS G12C inhibitors with improved selectivity and potency
5.2. Adoption of combination regimens pairing KRAS inhibitors with immune checkpoint blockade in solid tumors
5.3. Advancements in precision diagnostics for identifying KRAS mutation subtypes and treatment response biomarkers
5.4. Growing investment in pan-KRAS inhibitors targeting multiple KRAS mutations beyond G12C in clinical pipelines
5.5. Increasing focus on overcoming KRAS inhibitor resistance through novel allosteric binding strategies and combination approaches
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. KRAS Inhibitor Market, by Indication
8.1. Introduction
8.2. Colorectal Cancer
8.3. Non-Small Cell Lung Cancer
8.4. Pancreatic Cancer
9. KRAS Inhibitor Market, by Mechanism of Action
9.1. Introduction
9.2. Allosteric Inhibitors
9.3. Covalent Inhibitors
9.4. Non-Covalent Inhibitors
10. KRAS Inhibitor Market, by Mutation Type
10.1. Introduction
10.2. G12C
10.3. G12D
10.4. G12V
11. KRAS Inhibitor Market, by Dosage Form
11.1. Introduction
11.2. Injectable Solutions
11.3. Oral Tablets
12. KRAS Inhibitor Market, by End User
12.1. Introduction
12.2. Cancer Care Centers
12.3. Hospitals
12.4. Retail Pharmacies
12.5. Specialty Clinics
13. KRAS Inhibitor Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacy
13.3. Online Pharmacy
13.4. Retail Pharmacy
13.5. Specialty Pharmacy
14. Americas KRAS Inhibitor Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa KRAS Inhibitor Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific KRAS Inhibitor Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Amgen Inc.
17.3.2. Mirati Therapeutics, Inc.
17.3.3. Revolution Medicines, Inc.
17.3.4. Boehringer Ingelheim International GmbH
17.3.5. Janssen Pharmaceuticals, Inc.
17.3.6. Carmot Therapeutics, Inc.
17.3.7. Hua Medicine Co., Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. KRAS INHIBITOR MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL KRAS INHIBITOR MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL KRAS INHIBITOR MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 12. GLOBAL KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL KRAS INHIBITOR MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL KRAS INHIBITOR MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. KRAS INHIBITOR MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. KRAS INHIBITOR MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. KRAS INHIBITOR MARKET: RESEARCHAI
FIGURE 28. KRAS INHIBITOR MARKET: RESEARCHSTATISTICS
FIGURE 29. KRAS INHIBITOR MARKET: RESEARCHCONTACTS
FIGURE 30. KRAS INHIBITOR MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. KRAS INHIBITOR MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL KRAS INHIBITOR MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL KRAS INHIBITOR MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL KRAS INHIBITOR MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL KRAS INHIBITOR MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL KRAS INHIBITOR MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL KRAS INHIBITOR MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL KRAS INHIBITOR MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL KRAS INHIBITOR MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ALLOSTERIC INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ALLOSTERIC INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COVALENT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COVALENT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL KRAS INHIBITOR MARKET SIZE, BY NON-COVALENT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL KRAS INHIBITOR MARKET SIZE, BY NON-COVALENT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12C, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12C, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12D, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12D, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12V, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12V, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL KRAS INHIBITOR MARKET SIZE, BY INJECTABLE SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL KRAS INHIBITOR MARKET SIZE, BY INJECTABLE SOLUTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ORAL TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ORAL TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL KRAS INHIBITOR MARKET SIZE, BY CANCER CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL KRAS INHIBITOR MARKET SIZE, BY CANCER CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL KRAS INHIBITOR MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL KRAS INHIBITOR MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL KRAS INHIBITOR MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL KRAS INHIBITOR MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL KRAS INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL KRAS INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL KRAS INHIBITOR MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL KRAS INHIBITOR MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL KRAS INHIBITOR MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL KRAS INHIBITOR MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL KRAS INHIBITOR MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL KRAS INHIBITOR MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 87. CANADA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 88. CANADA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 89. CANADA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 90. CANADA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 91. CANADA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 92. CANADA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 93. CANADA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 94. CANADA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 95. CANADA KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. CANADA KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. CANADA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. CANADA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. MEXICO KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 100. MEXICO KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 101. MEXICO KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 102. MEXICO KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 103. MEXICO KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 104. MEXICO KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 105. MEXICO KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 106. MEXICO KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 107. MEXICO KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 108. MEXICO KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 109. MEXICO KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 110. MEXICO KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 113. BRAZIL KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 114. BRAZIL KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 123. ARGENTINA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 124. ARGENTINA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 125. ARGENTINA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 126. ARGENTINA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 127. ARGENTINA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 128. ARGENTINA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 129. ARGENTINA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 130. ARGENTINA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 131. ARGENTINA KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. ARGENTINA KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. ARGENTINA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 134. ARGENTINA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 150. UNITED KINGDOM KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 152. UNITED KINGDOM KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 154. UNITED KINGDOM KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 156. UNITED KINGDOM KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. UNITED KINGDOM KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. UNITED KINGDOM KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. GERMANY KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 162. GERMANY KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 163. GERMANY KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 164. GERMANY KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 165. GERMANY KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 166. GERMANY KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 167. GERMANY KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 168. GERMANY KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 169. GERMANY KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. GERMANY KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. GERMANY KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. GERMANY KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. FRANCE KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 174. FRANCE KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 175. FRANCE KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 176. FRANCE KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 177. FRANCE KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 178. FRANCE KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 179. FRANCE KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 180. FRANCE KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 181. FRANCE KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. FRANCE KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. FRANCE KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. FRANCE KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. RUSSIA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 186. RUSSIA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 187. RUSSIA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 188. RUSSIA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 189. RUSSIA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 190. RUSSIA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 191. RUSSIA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 192. RUSSIA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 193. RUSSIA KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. RUSSIA KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. RUSSIA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 196. RUSSIA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 197. ITALY KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 198. ITALY KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 199. ITALY KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 200. ITALY KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 201. ITALY KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 202. ITALY KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 203. ITALY KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 204. ITALY KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 205. ITALY KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. ITALY KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. ITALY KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. ITALY KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. SPAIN KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 210. SPAIN KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 211. SPAIN KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 212. SPAIN KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 213. SPAIN KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 214. SPAIN KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 215. SPAIN KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 216. SPAIN KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 217. SPAIN KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. SPAIN KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. SPAIN KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 220. SPAIN KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 234. SAUDI ARABIA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 236. SAUDI ARABIA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 238. SAUDI ARABIA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 240. SAUDI ARABIA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. SAUDI ARABIA KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. SAUDI ARABIA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 246. SOUTH AFRICA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 248. SOUTH AFRICA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 250. SOUTH AFRICA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 252. SOUTH AFRICA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. SOUTH AFRICA KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 256. SOUTH AFRICA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 257. DENMARK KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 258. DENMARK KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 259. DENMARK KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 260. DENMARK KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 261. DENMARK KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 262. DENMARK KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 263. DENMARK KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 264. DENMARK KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 265. DENMARK KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. DENMARK KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. DENMARK KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 268. DENMARK KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 269. NETHERLANDS KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 270. NETHERLANDS KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 271. NETHERLANDS KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 272. NETHERLANDS KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 273. NETHERLANDS KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 274. NETHERLANDS KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 275. NETHERLANDS KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 276. NETHERLANDS KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 277. NETHERLANDS KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 278. NETHERLANDS KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 279. NETHERLANDS KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 280. NETHERLANDS KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 281. QATAR KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 282. QATAR KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 283. QATAR KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 284. QATAR KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 285. QATAR KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 286. QATAR KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 287. QATAR KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 288. QATAR KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 289. QATAR KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. QATAR KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. QATAR KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 292. QATAR KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 293. FINLAND KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 294. FINLAND KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 295. FINLAND KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 296. FINLAND KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 297. FINLAND KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 298. FINLAND KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 299. FINLAND KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 300. FINLAND KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 301. FINLAND KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 302. FINLAND KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 303. FINLAND KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 304. FINLAND KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 305. SWEDEN KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 306. SWEDEN KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 307. SWEDEN KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 308. SWEDEN KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 309. SWEDEN KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 310. SWEDEN KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 311. SWEDEN KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 312. SWEDEN KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 313. SWEDEN KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 314. SWEDEN KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 315. SWEDEN KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 316. SWEDEN KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 317. NIGERIA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 318. NIGERIA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 319. NIGERIA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 320. NIGERIA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 321. NIGERIA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 322. NIGERIA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 323. NIGERIA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 324. NIGERIA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 325. NIGERIA KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 326. NIGERIA KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 327. NIGERIA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 328. NIGERIA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 329. EGYPT KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 330. EGYPT KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 331. EGYPT KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 332. EGYPT KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 333. EGYPT KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 334. EGYPT KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 335. EGYPT KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 336. EGYPT KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 337. EGYPT KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 338. EGYPT KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 339. EGYPT KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 340. EGYPT KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 341. TURKEY KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 342. TURKEY KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 343. TURKEY KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 344. TURKEY KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 345. TURKEY KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 346. TURKEY KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025-2030 (USD MILLION)
TABLE 347. TURKEY KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 348. TURKEY KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 349. TURKEY KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 350. TURKEY KRAS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 351. TURKEY KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 352. TURKEY KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 353. ISRAEL KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 354. ISRAEL KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 355. ISRAEL KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 356. ISRAEL KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 357. ISRAEL KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2024 (USD MILLION)
TABLE 358. ISRA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this KRAS Inhibitor market report include:
  • Amgen Inc.
  • Mirati Therapeutics, Inc.
  • Revolution Medicines, Inc.
  • Boehringer Ingelheim International GmbH
  • Janssen Pharmaceuticals, Inc.
  • Carmot Therapeutics, Inc.
  • Hua Medicine Co., Ltd.

Related Topics

Related Reports

KRAS Inhibitors Market, Drug Sales, Patent, Price & Clinical Trials Insight 2030 - Product Image

KRAS Inhibitors Market, Drug Sales, Patent, Price & Clinical Trials Insight 2030

  • Report
  • 240 Pages
  • Global
From
KRAS Inhibitors - Market Size, Target Population, Competitive Landscape & Market Forecast - 2034 - Product Image

KRAS Inhibitors - Market Size, Target Population, Competitive Landscape & Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
KRAS Mutant Cancer - Pipeline Insight, 2025 - Product Image

KRAS Mutant Cancer - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Therapeutic Applications of Nitric Oxide in Cancer and Inflammatory Disorders. Third International Conference on Therapeutic Application of Nitric Oxide in Cancer and Inflammatory Disorders - Product Image

Therapeutic Applications of Nitric Oxide in Cancer and Inflammatory Disorders. Third International Conference on Therapeutic Application of Nitric Oxide in Cancer and Inflammatory Disorders

  • Book
  • Global
Promising Cancer Therapeutic Drug Targets: Recent Advancements - Product Image

Promising Cancer Therapeutic Drug Targets: Recent Advancements

  • Book
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.